MAPT and tauopathy: Despite these different mechanisms, it appears that therapeutics to reduce the levels of hyperphosphorylated tau as well as therapeutics aimed at preventing cytoskeleton disruption remain as key targets for tauopathies (Corbo and Alonso, 2011).